Skip to main content

AbbVie Inc. stock price and financials

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$295.03+0.20%Close 13 Nov 2026
Market value
$525.9B
P/E
51.07
EV / EBITDA
20.44
Dividend yield
2.3%
Beta · 1 year
−0.02
Return · 1 year
+26.5%
52-week range$190.75 — $302.93

Share price close 16 Nov 2026

+4.8%1 monthHigh $297.07Low $282.68
$280$285$290$295$300Q3 FY2026 report filed 3 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+41.2%6 monthsHigh $297.07Low $209.41
$200$225$250$275$300Q2 FY2026 report filed 3 Aug 2026Q3 FY2026 report filed 3 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+30.0%year to dateHigh $297.07Low $197.38
$175$200$225$250$275$300Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 8 May 2026Q2 FY2026 report filed 3 Aug 2026Q3 FY2026 report filed 3 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+27.8%1 yearHigh $297.07Low $197.38
$175$200$225$250$275$300Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 8 May 2026Q2 FY2026 report filed 3 Aug 2026Q3 FY2026 report filed 3 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+116%3 yearsHigh $297.07Low $138.08
$100$150$200$250$300Q4 FY2023 report filed 20 Feb 2024Q1 FY2024 report filed 3 May 2024Q2 FY2024 report filed 7 Aug 2024Q3 FY2024 report filed 4 Nov 2024Q4 FY2024 report filed 14 Feb 2025Q1 FY2025 report filed 9 May 2025Q2 FY2025 report filed 4 Aug 2025Q3 FY2025 report filed 4 Nov 2025Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 8 May 2026Q2 FY2026 report filed 3 Aug 2026Q3 FY2026 report filed 3 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+391%10 yearsHigh $297.07Low $59.43
$0$100$200$300Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

AbbVie Inc. reported revenue of $61.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 8.6% from fiscal 2024. Net income was $4.23 billion and diluted earnings per share $2.36.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $17.4 billion, up 10.3% from a year earlier.

Figures from AbbVie Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 3 Nov 2026.

Against Health Care

Growth
Lower half
Revenue +6.0% a year over five years · 25th of 37
Profitability
Lower half
Return on invested capital 10.3%, five-year average · 20th of 38
Balance sheet
Lower half
Net debt 2.4× EBITDA · 24th of 38
Valuation
Dearer than most
P/E 51.1 · 30th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$61.16B+8.6%
Net income
$4.23B−1.2%
Diluted EPS
$2.36−1.3%
Gross margin
70.2%+0.2 pts
Free cash flow
$17.82B−0.1%
Net debt
$63.12B+1.1%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$20B$40B$60B$80BRevenue, FY16: $25.64BNet income, FY16: $5.95BFY16Revenue, FY17: $28.22BNet income, FY17: $5.31BFY17Revenue, FY18: $32.75BNet income, FY18: $5.69BFY18Revenue, FY19: $33.27BNet income, FY19: $7.88BFY19Revenue, FY20: $45.8BNet income, FY20: $4.62BFY20Revenue, FY21: $56.2BNet income, FY21: $11.54BFY21Revenue, FY22: $58.05BNet income, FY22: $11.84BFY22Revenue, FY23: $54.32BNet income, FY23: $4.86BFY23Revenue, FY24: $56.33BNet income, FY24: $4.28BFY24Revenue, FY25: $61.16BNet income, FY25: $4.23BFY25

Where the revenue comes from FY 2025 · $61.16B

AbbVie Inc. revenue by country, FY 2025
CountryRevenueShareChange
United States$46.60B76%+8.3%
All other countries$5.76B9.4%+5.7%
Germany$1.74B2.8%+18.6%
Japan$1.27B2.1%+13.5%
Canada$1.22B2.0%+12.3%
China$1.01B1.6%+9.7%
FR$806.0M1.3%+3.9%
Other lines (5)$2.75B4.5%—
Each line by fiscal year →

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 3 Nov 2026 · Full results →

Revenue
$17.40B+10.3% on a year
Gross margin
75.4%+9.0 pts on a year
Operating income
$6.27B+229% on a year
Net income
$4.22B+2168% on a year
Diluted EPS
$2.37+2270% on a year
Free cash flow
$7.30B+10.0% on a year

Comparable companies All of Health Care →

AbbVie Inc. beside the other S&P 500 members in Biotechnology, by market value.

AbbVie Inc. and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—
BiogenBIIB$37.52B+1.2%+56.9%+2.3%3.4%108.0
IncyteINCY$24.67B−0.6%+11.7%+24.9%6.7%61.2
ModernaMRNA—−3.4%+736%———
Regeneron PharmaceuticalsREGN—+0.4%+40.2%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%70.2%24.6%6.9%FY16FY19FY22FY25

AbbVie Inc. revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By country

AbbVie Inc. revenue by country, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$43.51B$45.71B+5.1%$41.88B−8.4%$43.03B+2.7%$46.60B+8.3%
All other countries$4.76B$4.84B+1.6%$5.04B+4.2%$5.45B+8.1%$5.76B+5.7%
Germany$1.22B$1.34B+9.6%$1.27B−5.5%$1.47B+15.7%$1.74B+18.6%
Japan$1.09B$956.0M−12.3%$1.01B+5.4%$1.12B+11.3%$1.27B+13.5%
Canada$1.40B$1.16B−17.0%$1.08B−7.2%$1.09B+1.1%$1.22B+12.3%
China$857.0M$912.0M+6.4%$950.0M+4.2%$917.0M−3.5%$1.01B+9.7%
FR$936.0M$787.0M−15.9%$780.0M−0.9%$776.0M−0.5%$806.0M+3.9%
United Kingdom$497.0M$462.0M−7.0%$417.0M−9.7%$522.0M+25.2%$626.0M+19.9%
ES$519.0M$506.0M−2.5%$501.0M−1.0%$528.0M+5.4%$609.0M+15.3%
IT$506.0M$444.0M−12.3%$484.0M+9.0%$511.0M+5.6%$580.0M+13.5%
BR$368.0M$430.0M+16.8%$439.0M+2.1%$464.0M+5.7%$478.0M+3.0%
AU$533.0M$508.0M−4.7%$472.0M−7.1%$463.0M−1.9%$459.0M−0.9%
Total revenue$56.20B$58.05B$54.32B$56.33B$61.16B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

AbbVie Inc. income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$25.64B$28.22B$32.75B$33.27B$45.80B$56.20B$58.05B$54.32B$56.33B$61.16B
Revenue growth+12.2%+10.1%+16.1%+1.6%+37.7%+22.7%+3.3%−6.4%+3.7%+8.6%
Gross profit$19.80B$21.17B$25.04B$25.83B$30.42B$38.75B$40.64B$33.90B$39.43B$42.96B
Operating income$9.34B$9.54B$6.38B$12.98B$11.36B$17.92B$18.12B$12.76B$9.14B$15.07B
Net income$5.95B$5.31B$5.69B$7.88B$4.62B$11.54B$11.84B$4.86B$4.28B$4.23B
Diluted EPS$3.63$3.30$3.66$5.28$2.72$6.45$6.63$2.72$2.39$2.36
Gross margin77.2%75.0%76.4%77.6%66.4%69.0%70.0%62.4%70.0%70.2%
Operating margin36.4%33.8%19.5%39.0%24.8%31.9%31.2%23.5%16.2%24.6%
Net margin23.2%18.8%17.4%23.7%10.1%20.5%20.4%9.0%7.6%6.9%

Cash flow

AbbVie Inc. cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$7.04B$9.96B$13.43B$13.32B$17.59B$22.78B$24.94B$22.84B$18.81B$19.03B
Capital expenditure$479.0M$529.0M$638.0M$552.0M$798.0M$787.0M$695.0M$777.0M$974.0M$1.21B
Free cash flow$6.56B$9.43B$12.79B$12.77B$16.79B$21.99B$24.25B$22.06B$17.83B$17.82B

Balance sheet and shares

AbbVie Inc. balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$5.10B$9.30B$7.29B$39.92B$8.45B$9.75B$9.20B$12.81B$5.52B$5.23B
Total debt$36.84B$37.37B$40.31B$67.09B$87.06B$77.58B$64.19B$60.29B$68.02B$68.38B
Shareholders' equity$4.64B$5.10B−$8.45B−$8.17B$13.08B$15.41B$17.25B$10.36B$3.33B−$3.27B
Diluted shares1.6B1.6B1.5B1.5B1.7B1.8B1.8B1.8B1.8B1.8B
Dividends per share$2.35$2.63$3.95$4.39$4.84$5.31$5.71$5.99$6.29$6.65

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

AbbVie Inc. quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$15.10B$13.34B$15.42B$15.78B$16.62B$15.00B$16.99B$17.40B
Revenue, year on year+5.6%+8.4%+6.6%+9.1%+10.0%+12.4%+10.2%+10.3%
Gross margin70.9%70.0%71.8%66.4%72.6%71.9%74.7%75.4%
Operating income−$1.49B$3.73B$4.89B$1.90B$4.54B$3.99B$6.43B$6.27B
Net income−$22.00M$1.29B$938.0M$186.0M$1.82B$695.0M$3.61B$4.22B
Diluted EPS−$0.02$0.72$0.52$0.10$1.02$0.39$2.03$2.37
Free cash flow$6.76B$1.40B$4.88B$6.64B$4.89B$3.56B$3.11B$7.30B

Operating KPIs

The operating figures AbbVie Inc. reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

AbbVie Inc. operating KPIs
KPILatestPeriodChange on a yearRecent periods
Skyrizi revenue$5.8Bquarter to 30 Sep 2026up 22.7%
Rinvoq revenue$2.7Bquarter to 30 Sep 2026up 23.9%
Botox Therapeutic revenue$1.1Bquarter to 30 Sep 2026up 9.6%
Vraylar revenue$1.1Bquarter to 30 Sep 2026up 14.3%
Venclexta revenue$803.0Mquarter to 30 Sep 2026up 10.6%
Humira revenue$683.0Mquarter to 30 Sep 2026down 31.2%
Botox Cosmetic revenue$669.0Mquarter to 30 Sep 2026up 5.0%
Imbruvica revenue$522.0Mquarter to 30 Sep 2026down 26.1%
Ubrelvy revenue$449.0Mquarter to 30 Sep 2026up 26.8%
Qulipta revenue$398.0Mquarter to 30 Sep 2026up 38.2%
Creon revenue$361.0Mquarter to 30 Sep 2026down 1.9%
Vyalev revenue$286.0Mquarter to 30 Sep 2026up 107.2%
Mavyret revenue$265.0Mquarter to 30 Sep 2026down 15.1%
Elahere revenue$224.0Mquarter to 30 Sep 2026up 31.8%
Juvederm Collection revenue$222.0Mquarter to 30 Sep 2026down 12.3%
Linzess/Constella revenue$175.0Mquarter to 31 Dec 2025down 24.9%
Ozurdex revenue$128.0Mquarter to 31 Dec 2025up 6.7%
Epkinly revenue$108.0Mquarter to 30 Sep 2026up 56.5%
Lumigan/Ganfort revenue$104.0Mquarter to 31 Dec 2025down 12.6%
Duodopa revenue$92.0Mquarter to 31 Dec 2025down 14.8%
Alphagan/Combigan revenue$54.0Mquarter to 31 Dec 2025down 30.8%
Immunology revenue$9.2Bquarter to 30 Sep 2026up 16.2%
Neuroscience revenue$3.4Bquarter to 30 Sep 2026up 19.3%
Oncology revenue$1.7Bquarter to 30 Sep 2026up 0.8%
Aesthetics revenue$1.2Bquarter to 30 Sep 2026down 1.4%
Eye Care revenue$580.0Mquarter to 31 Dec 2025down 10.2%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was AbbVie Inc.'s revenue in fiscal 2025?

$61.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was AbbVie Inc.'s net income in fiscal 2025?

$4.23 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were AbbVie Inc.'s diluted earnings per share in fiscal 2025?

$2.36 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is AbbVie Inc.'s gross margin?

70.2% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is AbbVie Inc.'s operating margin?

24.6% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did AbbVie Inc. generate in fiscal 2025?

$17.8 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does AbbVie Inc.'s revenue come from?

In fiscal 2025, by country: United States $46.60B (76%), All other countries $5.76B (9.4%), Germany $1.74B (2.8%), Japan $1.27B (2.1%), out of $61.16B in all, as stated in its annual report.

In the terminal

Twenty years of AbbVie Inc.'s figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans